Clinical management of Clostridium difficile -: Associated disease

被引：34

作者：

Miller, Mark A. ^{[1
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, Infect Prevent & Control, Div Infect Dis & Clin Microbiol, Montreal, PQ H3T 1E2, Canada

来源：

CLINICAL INFECTIOUS DISEASES | 2007年 / 45卷

关键词：

D O I：

10.1086/519257

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The incidence of Clostridium difficile-associated disease (CDAD) and its serious complications ( including colectomy and death) have been increasing worldwide. This phenomenon is strongly associated with the appearance of a new "hypervirulent" strain in several countries. More-effective strategies are needed for the prevention and treatment of this entity. This article will review the current approaches using antimicrobials, probiotics, immunomodulation, surgery, and miscellaneous adjuvants to prevent and treat this infection.

引用

收藏

页码：S122 / S128

页数：7

相关论文

共 64 条

[1] Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].

Aas, J ;

Gessert, CE ;

Bakken, JS .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585

[2] Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A [J].

Aboudola, S ;

Kotloff, KL ;

Kyne, L ;

Warny, M ;

Kelly, EC ;

Sougioultzis, S ;

Giannasca, PJ ;

Monath, TP ;

Kelly, CP .

INFECTION AND IMMUNITY, 2003, 71 (03) :1608-1610

[3]

[Anonymous], 1998, Am J Health Syst Pharm, V55, P1407

[4] Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis:: Case series and review of the literature [J].

Apisarnthanarak, A ;

Razavi, B ;

Mundy, LM .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) :690-696

[5] Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis [J].

Cherifi, S ;

Robberecht, J ;

Miendje, Y .

ACTA CLINICA BELGICA, 2004, 59 (04) :223-224

[6] Fulminant Clostridium difficile:: An underappreciated and increasing cause of death and complications [J].

Dallal, RM ;

Harbrecht, BG ;

Boujoukas, AJ ;

Sirio, CA ;

Farkas, LM ;

Lee, KK ;

Simmons, RL .

ANNALS OF SURGERY, 2002, 235 (03) :363-372

[7] PROSPECTIVE-STUDY OF ORAL TEICOPLANIN VERSUS ORAL VANCOMYCIN FOR THERAPY OF PSEUDOMEMBRANOUS COLITIS AND CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHEA [J].

DELALLA, F ;

NICOLIN, R ;

RINALDI, E ;

SCARPELLINI, P ;

RIGOLI, R ;

MANFRIN, V ;

TRAMARIN, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) :2192-2196

[8] Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea:: a systematic review [J].

Dendukuri, N ;

Costa, V ;

McGregor, M ;

Brophy, JM .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (02) :167-170

[9]

Dendukuri N, 2007, AM J GASTROENTEROL, V102, P201

[10] Risk factors for early recurrent Clostridium difficile -: Associated diarrhea [J].

Do, AN ;

Fridkin, SK ;

Yechouron, A ;

Banerjee, SN ;

Killgore, GE ;

Bourgault, AM ;

Jolivet, M ;

Jarvis, WR .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :954-959

← 1 2 3 4 5 6 7 →